Streetbeat News

Regulatory

MCHP

Microchip Technology has announced that its JAN transistors are now qualified to Enhanced Low Dose Radiation Sensitivity (ELDRS) standards, meeting MIL-STD-750 and various MIL-PRF specifications for defense applications.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 12:01 pm

ADIL

Adial Pharmaceuticals announced the publication of Phase 3 ONWARD study results in the European Journal of Internal Medicine, showing the efficacy of AD04 in reducing heavy drinking days among patients with specific genetic profiles. The study found minimal adverse events and high compliance, suggesting a promising treatment for alcohol use disorder.

Portfolio Pulse from Vandana Singh

June 20, 2024 | 12:00 pm

LLY

NVO

Eli Lilly & Co. (NYSE: LLY) has intensified its legal actions against counterfeit versions of its obesity drug, Zepbound, by filing lawsuits against various establishments for trademark violations, false advertising, and unfair competition. The company is addressing safety concerns related to counterfeit products and has made significant investments to meet the growing demand for its weight-loss and diabetes medications.

Portfolio Pulse from Benzinga Neuro

June 20, 2024 | 11:44 am

NTRB

Nutriband has provided an update on its Aversa Fentanyl product development program, aiming to complete the scale-up of the commercial manufacturing process and move towards a single Phase 1 human abuse potential study before filing an FDA application.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:29 am

HROW

Harrow has announced the manufacture of the first of three commercial-scale Process Performance Qualification (PPQ) batches of Triesence, a product used for visualization during vitrectomy and ocular inflammatory conditions. The second and third required PPQ batches are scheduled.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:27 am

DJT

Trump Media & Technology Group shares are trading lower after the SEC declared effectiveness of the registration statement on Form S-1 related to the resale by certain securityholders of certain shares and warrants.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:25 am

MNMD

MindMed has completed an end-of-phase 2 meeting with the FDA and reached alignment on the Phase 3 development strategy for MM120 in treating Generalized Anxiety Disorder (GAD). The company plans to initiate the Phase 3 clinical program in the second half of this year.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:13 am

EWU

The Bank of England has decided to leave the bank rate unchanged at 5.25%. This decision may have implications for various financial markets and instruments, including the iShares MSCI United Kingdom ETF (EWU).

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:12 am

ATAI

Atai Life Sciences announced an update on Beckley Psytech's Phase 1/2A trial of ELE-101 for Major Depressive Disorder. Initial Phase 1 results were positive, and the first patients have been dosed in Phase 2A. Results are expected in H2 2024.

Portfolio Pulse from Benzinga Newsdesk

June 20, 2024 | 11:05 am

META

A report reveals that Instagram's algorithm continues to recommend sexually explicit content to teen accounts, despite Meta's promises to provide an age-appropriate experience. Tests showed that within minutes of logging in, teens were exposed to adult content. Meta dismissed the findings as unrepresentative. Similar tests on Snapchat and TikTok did not yield the same results.

Portfolio Pulse from Benzinga Neuro

June 20, 2024 | 10:48 am